This observation not only suggests that PD-L1 is a suboptimal biomarker to predict patient response to pembrolizumab but also that the suppressive signals of the PD-1 pathway are not solely responsible for the attenuated immune response in the tumor microenvironment (TME)25,29. This evidence concerns the gene PDCD1 and neoplasm.